Codexis, Inc. CDXS
We take great care to ensure that the data presented and summarized in this overview for CODEXIS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDXS
View all-
Opaleye Management Inc. Boston, MA8.77MShares$43.9 Million4.93% of portfolio
-
Casdin Capital, LLC New York, NY8.1MShares$40.5 Million1.94% of portfolio
-
Black Rock Inc. New York, NY6.79MShares$33.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.15MShares$20.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.97MShares$14.8 Million0.54% of portfolio
-
Telemark Asset Management, LLC Boston, MA2.7MShares$13.5 Million0.89% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN2.39MShares$11.9 Million0.0% of portfolio
-
Baillie Gifford & CO1.81MShares$9.07 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.64MShares$8.22 Million0.0% of portfolio
-
State Street Corp Boston, MA1.55MShares$7.76 Million0.0% of portfolio
Latest Institutional Activity in CDXS
Top Purchases
Top Sells
About CDXS
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Insider Transactions at CDXS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 14
2025
|
Christos Richards |
BUY
Grant, award, or other acquisition
|
Direct |
44,150
+50.0%
|
-
|
|
Dec 31
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.12%
|
$40,000
$4.66 P/Share
|
|
Dec 30
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
35,000
+0.41%
|
$140,000
$4.7 P/Share
|
|
Nov 07
2024
|
Raymond De Vre |
BUY
Grant, award, or other acquisition
|
Direct |
47,846
+50.0%
|
-
|
|
Oct 25
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.29%
|
$50,000
$2.91 P/Share
|
|
Oct 10
2024
|
Georgia Erbez Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Oct 10
2024
|
Alison Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+25.16%
|
-
|
|
Sep 25
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.06%
|
$10,000
$2.86 P/Share
|
|
Sep 24
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
80,000
+0.93%
|
$160,000
$2.94 P/Share
|
|
Sep 23
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
45,000
+0.53%
|
$90,000
$2.94 P/Share
|
|
Sep 20
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,055,000
+13.0%
|
$3,165,000
$3.01 P/Share
|
|
Sep 18
2024
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
61,000
+1.79%
|
$183,000
$3.16 P/Share
|
|
Jun 11
2024
|
Byron L Dorgan |
BUY
Grant, award, or other acquisition
|
Direct |
30,120
+11.87%
|
-
|
|
Jun 11
2024
|
Esther Martinborough |
BUY
Grant, award, or other acquisition
|
Direct |
30,120
+25.49%
|
-
|
|
Jun 11
2024
|
Alison Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,120
+23.38%
|
-
|
|
Jun 11
2024
|
H Stewart Parker |
BUY
Grant, award, or other acquisition
|
Direct |
30,120
+22.69%
|
-
|
|
Jun 11
2024
|
Rahul Singhvi |
BUY
Grant, award, or other acquisition
|
Direct |
30,120
+23.87%
|
-
|
|
Jun 11
2024
|
Dennis P Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
30,120
+21.98%
|
-
|
|
Jun 11
2024
|
David V Smith |
BUY
Grant, award, or other acquisition
|
Direct |
30,120
+31.76%
|
-
|
|
Jan 01
2024
|
Stephen George Dilly |
BUY
Grant, award, or other acquisition
|
Direct |
143,425
+19.76%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 1.32M shares |
|---|---|
| Grant, award, or other acquisition | 403K shares |